The oncology landscape is undergoing its most significant transformation since the advent of checkpoint inhibitors, driven by the clinical and commercial success of mRNA technology. Unlike traditional vaccines that prevent disease, therapeutic mRNA cancer vaccines are designed to train the patient’s own immune system to identify and destroy malignant cells. The mRNA Cancer Vaccines...

The North America cancer vaccines market is expected to maintain a significant position in the global landscape through 2031, supported by the rising incidence of cancer, substantial healthcare expenditure, advanced research infrastructure, and increasing investments in innovative cancer immunotherapies. The region comprises the US, Canada, and Mexico and held a significant share of the global...

Immunotherapy innovation is expanding rapidly as the Tumour Cell Vaccine Market explores therapeutic vaccination strategies designed to activate immune responses against existing cancers. Unlike preventive vaccines, tumour cell vaccines introduce modified cancer cells or tumor-derived antigens to teach immune systems to recognize malignant cells as threats. These therapies aim to establish...

The US cancer vaccines market represents a key component of the North American landscape, supported by the high prevalence of cancer, sophisticated healthcare infrastructure, strong pharmaceutical capabilities, and considerable spending on oncology research and development. According to The Insight Partners, the United States is a key market, with growth supported by the increasing prevalence...